Study Details

Back
Study ID 8273-CL-0102
Study Title An open-label, phase 1 dose escalation study of oral ASP8273 in subjects with non-small-cell lung cancer (NSCLC) who have epidermal growth factor receptor (EGFR) mutations
Clinicaltrials.gov Identifier NCT02113813
Compound Name ASP8273 / naquotinib mesilate
Medical Indication or Disease Non-small cell lung cancer
Study Sponsor Astellas Pharma Global Development, Inc
Collaborator Not Applicable
Study Start Date 09-Apr-2014
Study Completion Date 11-Feb-2019
Clinical Study Result
Select the language
English
Plain Language Summary
Select the language
English

QUICK SEARCH

USEFUL LINKS